Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Oct;42(10):887-95.
doi: 10.1093/jjco/hys121. Epub 2012 Jul 27.

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma

Motoo Nagane  1 , Ryo Nishikawa, Yoshitaka Narita, Hiroyuki Kobayashi, Shingo Takano, Nobusada Shinoura, Tomokazu Aoki, Kazuhiko Sugiyama, Junichi Kuratsu, Yoshihiro Muragaki, Yutaka Sawamura, Masao Matsutani
Affiliations
Clinical Trial

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma

Motoo Nagane et al. Jpn J Clin Oncol. 2012 Oct.

Abstract

Objective: This single-arm, open-label, Phase II study evaluated the efficacy and safety of single-agent bevacizumab, a monoclonal antibody against vascular endothelial growth factor, in Japanese patients with recurrent malignant glioma.

Methods: Patients with histologically confirmed, measurable glioblastoma or World Health Organization Grade III glioma, previously treated with temozolomide plus radiotherapy, received 10 mg/kg bevacizumab intravenous infusion every 2 weeks. The primary endpoint was 6-month progression-free survival in the patients with recurrent glioblastoma.

Results: Of the 31 patients enrolled, 29 (93.5%) had glioblastoma and 2 (6.5%) had Grade III glioma. Eleven (35.5%) patients were receiving corticosteroids at baseline; 17 (54.8%) and 14 (45.2%) patients had experienced one or two relapses, respectively. The 6-month progression-free survival rate in the 29 patients with recurrent glioblastoma was 33.9% (90% confidence interval, 19.2-48.5) and the median progression-free survival was 3.3 months. The 1-year survival rate was 34.5% with a median overall survival of 10.5 months. There were eight responders (all partial responses) giving an objective response rate of 27.6%. The disease control rate was 79.3%. Eight of the 11 patients taking corticosteroids at baseline reduced their dose or discontinued corticosteroids during the study. Bevacizumab was well-tolerated and Grade ≥3 adverse events of special interest to bevacizumab were as follows: hypertension [3 (9.7%) patients], congestive heart failure [1 (3.2%) patient] and venous thromboembolism [1 (3.2%) patient]. One asymptomatic Grade 1 cerebral hemorrhage was observed, which resolved without treatment.

Conclusion: Single-agent bevacizumab provides clinical benefit for Japanese patients with recurrent glioblastoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Progression-free survival determined by independent radiology facility in patients with recurrent glioblastoma (GBM).
Figure 2.
Figure 2.
Overall survival in patients with recurrent GBM.
Figure 3.
Figure 3.
Waterfall plot showing the change in tumor size from baseline.
See this image and copyright information in PMC

References

    1. Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus. 2006;20:E5. - PubMed
    1. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol. 2009;472:323–42. - PubMed
    1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66. - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. - PubMed
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers V.2.2011 http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf .

Publication types

MeSH terms